Strengthening Global IP for Next-Generation mRNA Innovation

Combined Therapeutics continues to strengthen its Intellectual Property position, supported by four solid patent families protecting our MOP platform across key markets. Our granted U.S. patents provide a strong commercial position and validate the novelty of our approach to tissue-specific mRNA expression. This evolving IP estate reinforces the long-term value of our next-generation mRNA vaccines and supports productive partnership discussions with leading pharmaceutical companies.